Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections

被引:88
|
作者
Obeid, Anthony [1 ]
Gao, Xinxiao [1 ,2 ]
Ali, Ferhina S. [1 ]
Talcott, Katherine E. [1 ]
Aderman, Christopher M. [1 ]
Hyman, Leslie [3 ]
Ho, Allen C. [1 ]
Hsu, Jason [1 ]
机构
[1] Wills Eye Hosp & Res Inst, Retina Serv, Mid Atlantic Retina, Philadelphia, PA USA
[2] Capital Med Univ, Beijing Anzhen Hosp, Beijing, Peoples R China
[3] Wills Eye Hosp & Res Inst, Vis Res Ctr, Philadelphia, PA USA
关键词
UNITED-STATES; MEDICARE BENEFICIARIES; EYE EXAMINATIONS; MACULAR EDEMA; DISTRUST; TRIAL; CARE;
D O I
10.1016/j.ophtha.2018.02.034
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Loss to follow-up (LTFU) may contribute to vision loss in patients with active proliferative diabetic retinopathy (PDR). The aim of this study is to determine and compare the rates of LTFU in patients with PDR receiving panretinal photocoagulation (PRP) or intravitreal injections (IVIs) with anti-vascular endothelial growth factor (VEGF) over approximately 4 years. Moreover, this study evaluates various risk factors for LTFU. Design: Retrospective cohort study. Participants: A total of 2302 patients with PDR receiving IVIs with anti-VEGF or PRP between January 1, 2012, and April 20, 2016. Methods: Intervals between each procedure and the subsequent follow-up visit were measured. Loss to follow-up was defined as at least 1 interval exceeding 12 months duration. Main Outcome Measures: The LTFU rates and associated risk factors. Results: A total of 1718 patients (74.6%) followed up postprocedure and 584 patients (25.4%) were LTFU over approximately 4 years. Of the patients receiving PRP, 28.0% were LTFU compared with 22.1% of patients receiving IVI with anti-VEGF (P = 0.001). The LTFU rates decreased as age increased, with rates of 28.1% for patients aged <= 55 years, 27.0% for patients aged 56 to 65 years, and 20.9% for patients aged >65 years (P = 0.002). Loss to follow-up also differed by race, with rates of 19.4% for whites, 30.2% for African Americans, 19.7% for Asians, 38.0% for Hispanics, Native Americans, and Pacific Islanders, and 34.9% for patients of unreported race (P < 0.001). The LTFU rates also increased as regional average adjusted gross incomes (AGIs) decreased, with rates of 33.9% for patients with regional average AGI of <=$40 000, 24.0% for patients with regional average AGI from $41 000 to $80 000, and 19.7% for patients with regional average AGI >$80 000 (P < 0.001). Procedure type, age, race, and regional average AGI were all significant (P < 0.05) independent risk factors of LTFU in the multivariate regression. Conclusions: A large proportion of patients with PDR were LTFU after receiving PRP or an anti-VEGF injection over approximately 4 years. Key risk factors included age, race, and regional average AGI. (C) 2018 by the American Academy of Ophthalmology
引用
收藏
页码:1386 / 1392
页数:7
相关论文
共 50 条
  • [41] Fever after intravitreal anti-VEGF injections
    Ioannis D. Ladas
    Athanasios I. Kotsolis
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 295 - 296
  • [42] Fever after intravitreal anti-VEGF injections
    Ladas, Ioannis D.
    Kotsolis, Athanasios I.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (02) : 295 - 296
  • [43] Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy
    Takayama, Kei
    Someya, Hideaki
    Yokoyama, Hiroshi
    Kimura, Takeshi
    Takamura, Yoshihiro
    Morioka, Masakazu
    Terasaki, Hiroto
    Ueda, Tetsuo
    Ogata, Nahoko
    Kitano, Shigehiko
    Tashiro, Maki
    Sakamoto, Taiji
    Takeuchi, Masaru
    PLOS ONE, 2021, 16 (10):
  • [44] Impact of intravitreal anti-VEGF therapy on intraretinal microvascular abnormalities in proliferative diabetic retinopathy
    Daniele De Geronimo
    Mariacristina Parravano
    Riccardo Sacconi
    Serena Fragiotta
    Daniela Giannini
    Eliana Costanzo
    Monica Varano
    Giuseppe Querques
    Acta Diabetologica, 2024, 61 : 525 - 528
  • [45] The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment
    Tremolada, Gemma
    Del Turco, Claudia
    Lattanzio, Rosangela
    Maestroni, Silvia
    Maestroni, Anna
    Bandello, Francesco
    Zerbini, Gianpaolo
    EXPERIMENTAL DIABETES RESEARCH, 2012,
  • [46] Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy
    Mariacristina Parravano
    Daniele De Geronimo
    Riccardo Sacconi
    Daniela Giannini
    Eliana Costanzo
    Serena Fragiotta
    Pasquale Viggiano
    Monica Varano
    Giuseppe Querques
    Ophthalmology and Therapy, 2022, 11 : 2117 - 2128
  • [47] Ocular blood flow velocities in patients with proliferative diabetic retinopathy after panretinal photocoagulation
    Mendivil, A
    SURVEY OF OPHTHALMOLOGY, 1997, 42 : S89 - S95
  • [48] Impact of intravitreal anti-VEGF therapy on intraretinal microvascular abnormalities in proliferative diabetic retinopathy
    De Geronimo, Daniele
    Parravano, Mariacristina
    Sacconi, Riccardo
    Fragiotta, Serena
    Giannini, Daniela
    Costanzo, Eliana
    Varano, Monica
    Querques, Giuseppe
    ACTA DIABETOLOGICA, 2024, 61 (04) : 525 - 528
  • [49] PANRETINAL PHOTOCOAGULATION COMBINED WITH INTRAVITREAL BEVACIZUMAB IN HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY
    Cho, Won Bin
    Oh, Se Beum
    Moon, Jun Woong
    Kim, Hyung Chan
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (04): : 516 - 522
  • [50] Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy
    Parravano, Mariacristina
    De Geronimo, Daniele
    Sacconi, Riccardo
    Giannini, Daniela
    Costanzo, Eliana
    Fragiotta, Serena
    Viggiano, Pasquale
    Varano, Monica
    Querques, Giuseppe
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (06) : 2117 - 2128